Skip to main content
SpringerLink
Log in

Post-angioplasty and In-stent Restenosis

  • Chapter
  • First Online:
Textbook of Catheter-Based Cardiovascular Interventions

  • 440 Accesses

Abstract

Restenosis is the Achilles’ heel of endovascular therapy for peripheral artery disease. Long-term care of patients following arterial interventions must include aggressive modification of cardiovascular risk factors and surveillance of all arterial beds. Intervention-specific surveillance should include clinical, physiologic, and anatomic evaluation using physical examination, vascular testing, and arterial ultrasound. Detection of restenosis is not a stand-alone indication for re-intervention because there is no single pharmacologic or invasive therapy that treats restenosis in an effective and durable manner. The decision to re-intervene must be patient-specific. There is wide gap between the clinical management strategies for restenosis and evidence-based medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:e71–e126.

    Article  PubMed  Google Scholar 

  2. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–76.

    Article  PubMed  Google Scholar 

  3. Iida O, Takahara M, Soga Y, et al. 1-year results of the ZEPHYR Registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv. 2015;8:1105–12.

    Article  PubMed  Google Scholar 

  4. Rowe VL, Lee W, Weaver FA, Etzioni D. Patterns of treatment for peripheral arterial disease in the United States: 1996–2005. J Vasc Surg. 2009;49:910–7.

    Article  PubMed  Google Scholar 

  5. Baker JD, Dix DE. Variability of Doppler ankle pressures with arterial occlusive disease: an evaluation of ankle index and brachial-ankle pressure gradient. Surgery. 1981;89:134–7.

    PubMed  CAS  Google Scholar 

  6. Mills JL, Harris EJ, Taylor LM Jr, Beckett WC, Porter JM. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. J Vasc Surg. 1990;12:379–86. discussion 87–9.

    Article  PubMed  CAS  Google Scholar 

  7. Lundell A, Lindblad B, Bergqvist D, Hansen F. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study. J Vasc Surg. 1995;21:26–33. discussion 4.

    Article  PubMed  CAS  Google Scholar 

  8. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the vein graft surveillance randomised trial (VGST). Circulation. 2005;112:1985–91.

    Article  PubMed  CAS  Google Scholar 

  9. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67.

    Article  PubMed  Google Scholar 

  10. Back MR, Novotney M, Roth SM, et al. Utility of duplex surveillance following iliac artery angioplasty and primary stenting. J Endovasc Ther. 2001;8:629–37.

    PubMed  CAS  Google Scholar 

  11. Baril DT, Rhee RY, Kim J, Makaroun MS, Chaer RA, Marone LK. Duplex criteria for determination of in-stent stenosis after angioplasty and stenting of the superficial femoral artery. J Vasc Surg. 2009;49:133–8. discussion 9.

    Article  PubMed  Google Scholar 

  12. Baril DT, Marone LK. Duplex evaluation following femoropopliteal angioplasty and stenting: criteria and utility of surveillance. Vasc Endovasc Surg. 2012;46:353–7.

    Article  Google Scholar 

  13. Connors G, Todoran TM, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay S. Percutaneous revascularization of long femoral artery lesions for claudication: patency over 2.5 years and impact of systematic surveillance. Catheter Cardiovasc Interv. 2011;77:1055–62.

    Article  PubMed  Google Scholar 

  14. Hamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation. 2011;123:87–97.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48:32–6.

    Article  PubMed  Google Scholar 

  16. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18:433–40.

    Article  PubMed  CAS  Google Scholar 

  17. Schlager O, Francesconi M, Haumer M, et al. Duplex sonography versus angiography for assessment of femoropopliteal arterial disease in a “real-world” setting. J Endovasc Ther. 2007;14:452–9.

    Article  PubMed  Google Scholar 

  18. Troutman DA, Madden NJ, Dougherty MJ, Calligaro KD. Duplex ultrasound diagnosis of failing stent grafts placed for occlusive disease. J Vasc Surg. 2014;60:1580–4.

    Article  PubMed  Google Scholar 

  19. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–88.

    Article  PubMed  CAS  Google Scholar 

  20. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285–92.

    Article  PubMed  CAS  Google Scholar 

  21. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.

    Article  PubMed  CAS  Google Scholar 

  22. Patel MR, Conte MS, Cutlip DE, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931–41.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shammas NW, Kapalis MJ, Dippel EJ, et al. Clinical and angiographic predictors of restenosis following renal artery stenting. J Invasive Cardiol. 2004;16:10–3.

    PubMed  Google Scholar 

  24. Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78:611–7.

    Article  PubMed  Google Scholar 

  25. Dube H, Clifford AG, Barry CM, Schwarten DE, Schwartz LB. Comparison of the vascular responses to balloon-expandable stenting in the coronary and peripheral circulations: long-term results in an animal model using the TriMaxx stent. J Vasc Surg. 2007;45:821–7.

    Article  PubMed  Google Scholar 

  26. Schillinger M, Exner M, Mlekusch W, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology. 2002;225:21–6.

    Article  PubMed  Google Scholar 

  27. Schillinger M, Exner M, Mlekusch W, et al. Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology. 2003;227:419–25.

    Article  PubMed  Google Scholar 

  28. Laxdal E, Eide GE, Wirsching J, et al. Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the above-knee femoro-popliteal artery. Eur J Vasc Endovasc Surg. 2004;28:410–7.

    Article  PubMed  CAS  Google Scholar 

  29. Iida O, Takahara M, Soga Y, et al. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery. JACC Cardiovasc Interv. 2014;7:792–8.

    Article  PubMed  Google Scholar 

  30. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23.

    Article  PubMed  Google Scholar 

  31. Soga Y, Iida O, Hirano K, et al. Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg. 2011;54:1058–66.

    Article  PubMed  Google Scholar 

  32. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008;48:144–9.

    Article  PubMed  Google Scholar 

  33. Soga Y, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53:48–53.

    Article  PubMed  CAS  Google Scholar 

  34. Iida O, Yokoi H, Soga Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013;127:2307–15.

    Article  PubMed  CAS  Google Scholar 

  35. Iftikhar O, Oliveros K, Tafur AJ, Casanegra AI. Prevention of femoropopliteal in-stent restenosis with cilostazol: a meta-analysis. Angiology. 2016;67:549–55.

    Article  PubMed  CAS  Google Scholar 

  36. Zen K, Takahara M, Iida O, et al. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. J Vasc Surg. 2017;65:720–5.

    Article  PubMed  Google Scholar 

  37. Kufner S, Hausleiter J, Ndrepepa G, et al. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc Interv. 2009;2:1142–8.

    Article  PubMed  Google Scholar 

  38. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004;110:790–5.

    Article  PubMed  CAS  Google Scholar 

  39. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol. 2006;47:1522–9.

    Article  PubMed  CAS  Google Scholar 

  40. Waksman R, Ajani AE, Pichard AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol. 2004;44:1386–92.

    PubMed  CAS  Google Scholar 

  41. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial. J Am Coll Cardiol. 1997;30:855–62.

    Article  PubMed  CAS  Google Scholar 

  42. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997;337:365–72.

    Article  PubMed  CAS  Google Scholar 

  43. Gallino A, Do DD, Alerci M, et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. J Endovasc Ther. 2004;11:595–604.

    Article  PubMed  Google Scholar 

  44. El Sayed H, Kerensky R, Stecher M, Mohanty P, Davies M. A randomized phase II study of Xilonix, a targeted therapy against interleukin 1alpha, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. J Vasc Surg. 2016;63:133–41 e1.

    Article  PubMed  Google Scholar 

  45. Shin SH, Baril DT, Chaer RA, Makaroun MS, Marone LK. Cryoplasty offers no advantage over standard balloon angioplasty for the treatment of in-stent stenosis. Vascular. 2013;21:349–54.

    Article  PubMed  CAS  Google Scholar 

  46. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology. 2008;248:297–302.

    Article  PubMed  Google Scholar 

  47. Virga V, Stabile E, Biamino G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7:411–5.

    Article  PubMed  Google Scholar 

  48. Grotti S, Liistro F, Angioli P, et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study. J Endovasc Ther. 2016;23:52–7.

    Article  PubMed  Google Scholar 

  49. Bague N, Julia P, Sauguet A, et al. Femoropopliteal in-stent restenosis repair: midterm outcomes after paclitaxel eluting balloon use (PLAISIR trial). Eur J Vasc Endovasc Surg. 2017;53:106–13.

    Article  PubMed  CAS  Google Scholar 

  50. Kinstner CM, Lammer J, Willfort-Ehringer A, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC Cardiovasc Interv. 2016;9:1386–92.

    Article  PubMed  Google Scholar 

  51. Krankenberg H, Tubler T, Ingwersen M, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized femoral artery in-stent restenosis (FAIR) trial. Circulation. 2015;132:2230–6.

    Article  PubMed  CAS  Google Scholar 

  52. Stahlhoff S, Donas KP, Torsello G, Osada N, Herten M. Drug-eluting vs standard balloon angioplasty for iliac stent restenosis: midterm results. J Endovasc Ther. 2015;22:314–8.

    Article  PubMed  Google Scholar 

  53. Javed U, Balwanz CR, Armstrong EJ, et al. Mid-term outcomes following endovascular re-intervention for iliac artery in-stent restenosis. Catheter Cardiovasc Interv. 2013;82:1176–84.

    Article  PubMed  Google Scholar 

  54. Shammas NW, Shammas GA, Banerjee S, Popma JJ, Mohammad A, Jerin M. JetStream rotational and aspiration atherectomy in treating in-stent restenosis of the femoropopliteal arteries: results of the JETSTREAM-ISR feasibility study. J Endovasc Ther. 2016;23:339–46.

    Article  PubMed  Google Scholar 

  55. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48:1573–8.

    Article  PubMed  Google Scholar 

  56. Trentmann J, Charalambous N, Djawanscher M, Schafer J, Jahnke T. Safety and efficacy of directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal artery. J Cardiovasc Surg. 2010;51:551–60.

    CAS  Google Scholar 

  57. Shammas NW, Shammas GA, Jerin M. Differences in patient selection and outcomes between SilverHawk atherectomy and laser ablation in the treatment of femoropopliteal in-stent restenosis: a retrospective analysis from a single center. J Endovasc Ther. 2013;20:844–52.

    Article  PubMed  Google Scholar 

  58. Shammas NW, Shammas GA, Hafez A, Kelly R, Reynolds E, Shammas AN. Safety and one-year revascularization outcome of excimer laser ablation therapy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. Cardiovasc Revasc Med. 2012;13:341–4.

    Article  PubMed  Google Scholar 

  59. Yeo KK, Malik U, Laird JR. Outcomes following treatment of femoropopliteal in-stent restenosis: a single center experience. Catheter Cardiovasc Interv. 2011;78:604–8.

    Article  PubMed  Google Scholar 

  60. Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015;8:92–101.

    Article  PubMed  Google Scholar 

  61. Schmidt A, Zeller T, Sievert H, et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther. 2014;21:52–60.

    Article  PubMed  Google Scholar 

  62. van den Berg JC, Pedrotti M, Canevascini R, Chimchila Chevili S, Giovannacci L, Rosso R. In-stent restenosis: mid-term results of debulking using excimer laser and drug-eluting balloons: sustained benefit? J Invasive Cardiol. 2014;26:333–7.

    PubMed  Google Scholar 

  63. Bosiers M, Deloose K, Callaert J, et al. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial. J Endovasc Ther. 2015;22:1–10.

    Article  PubMed  Google Scholar 

  64. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274–81.

    Article  PubMed  Google Scholar 

  65. Schopohl B, Leirmann D, Pohlit LJ, et al. 192IR endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. Int J Radiat Oncol Biol Phys. 1996;36:835–40.

    Article  PubMed  CAS  Google Scholar 

  66. Wolfram RM, Budinsky AC, Pokrajac B, Potter R, Minar E. Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery–the Vienna experience. Radiology. 2005;236:338–42.

    Article  PubMed  Google Scholar 

  67. Pokrajac B, Kirisits C, Schmid R, et al. Beta endovascular brachytherapy using CO2-filled centering catheter for treatment of recurrent superficial femoropopliteal artery disease. Cardiovasc Revasc Med. 2009;10:162–5.

    Article  PubMed  Google Scholar 

  68. Werner M, Scheinert D, Henn M, et al. Endovascular brachytherapy using liquid Beta-emitting rhenium-188 for the treatment of long-segment femoropopliteal in-stent stenosis. J Endovasc Ther. 2012;19:467–75.

    Article  PubMed  Google Scholar 

  69. Levy MTT, Kinlay S, Eisenhauer A, Sobieszczyk P. Endovascular brachytherapy as an adjunctive treatment for long segment lower extremity in-stent restenosis. Catheter Cardiovasc Interv. 2010;75:S93.

    Google Scholar 

  70. Ho KJ, Devlin PM, Madenci AL, et al. High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis. J Vasc Surg. 2017;65:734–43.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Cardiovascular Division, Vascular Medicine Section, Brigham and Women’s Hospital, Boston, MA, USA

    Piotr Sobieszczyk MD

Authors
  1. Piotr Sobieszczyk MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Piotr Sobieszczyk MD .

Editor information

Editors and Affiliations

  1. Middle German Heart Center and Health Care Center Bitterfeld-Wolfen, gGmbH, Bitterfeld-Wolfen, Germany

    Peter Lanzer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sobieszczyk, P. (2018). Post-angioplasty and In-stent Restenosis. In: Lanzer, P. (eds) Textbook of Catheter-Based Cardiovascular Interventions. Springer, Cham. https://doi.org/10.1007/978-3-319-55994-0_87

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55994-0_87

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55993-3

  • Online ISBN: 978-3-319-55994-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation